Dr. Richard Sachse holds a degree in medicine from the Friedrich-Alexander-University Erlangen, Germany, and a board certification in Clinical Pharmacology. With more than 25 years experience as a physician and scientist, he has extensive expertise in pharmaceutical development covering the entire value chain from preclinical through to registration. In addition to registration studies, he is especially experienced in the design and implementation of translational programs to bridge research programs to the clinic.
Prior to joining SOTIO he was leading the medical, scientific, regulatory and pharmacovigilance activities as CSO at Neovii. As CSO/CMO at Aeterna Zentaris he was successful in achieving FDA approval of Macimorelin. This was preceeded by a steady growth through several managerial career steps at Bayer, Peptor, Schwarz Pharma, UCB and Boehringer Ingelheim. He started his medical and scientific career as a Postdoctoral Fellow at the National Cancer Center Research Institute, Tokyo, Japan and later as a Resident in Internal Medicine at the University Erlangen, Germany.